CHENGDU, China, Jan. 5, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors.

In December 2025, Kelun-Biotech and Crescent Biopharma, Inc. (“Crescent”) entered into a strategic collaboration for SKB105/CR-003 and SKB118 (a PD-1 x VEGF bispecific antibody, also known as CR-001). Under the collaboration, Kelun-Biotech granted Crescent exclusive rights to research, develop, manufacture and commercialize SKB105/CR-003 in the United States, Europe and all other markets outside of Greater China. In addition, Crescent granted Kelun-Biotech exclusive rights to research, develop, manufacture and commercialize SKB118/CR-001 in Greater China. The IND application for SKB118/CR-001 has been cleared by the U.S. Food and Drug Administration (FDA) with a global Phase I/II clinical trial for the treatment of advanced solid tumors is set to commence shortly. Kelun-Biotech plans to submit an IND application for SKB118/CR-001 to the Center for Drug Evaluation of the National Medical Products Administration of China in the near future.

About SKB105 (also known as CR-003)

SKB105 is a differentiated ADC targeting ITGB6 with a topoisomerase I inhibitor payload. ITGB6 is overexpressed in many solid tumors, but shows minimal to no expression in most normal tissues, thereby potentially reducing the risk of systemic toxicity and off-target effects. SKB105 incorporates proprietary Kthiol^® irreversible conjugation technology, linking an anti-ITGB6 fully human Immunoglobulin G1 (IgG1) monoclonal antibody (mAb) to a clinically validated cleavable linker. This design aims to enhance stability and tumor-specific payload delivery while reducing adverse effects. In preclinical models, SKB105 demonstrated a favorable efficacy, safety, and pharmacokinetic (PK) profile.

About SKB118(also known as CR-001)

SKB118/CR-001 is a tetravalent bispecific antibody being developed for the treatment of solid tumors that combines two complementary, validated mechanisms in oncology via a blockade of PD-1 and VEGF. PD-1 checkpoint inhibition is aimed at restoring T cells’ ability to recognize and destroy tumor cells, and blocking VEGF is intended for reducing blood supply to tumor cells and inhibiting tumor growth. In preclinical studies, SKB118/CR-001 demonstrated cooperative pharmacology with increased binding to PD-1 and signal blockade in the presence of VEGF as well as robust anti-tumor activity. SKB118/CR-001’s anti-VEGF activity may also normalize the vasculature at the tumor site, which has the potential to improve the localization and effectiveness of combination therapies, particularly in conjunction with ADCs. 

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

DALLAS, Jan. 5, 2026 /PRNewswire/ — Cango Inc. (NYSE: CANG) (“Cango” or the “Company”), a leading Bitcoin miner leveraging its global operations to develop an integrated energy and AI compute platform, today published its Bitcoin production and mining operations update for December 2025.

Bitcoin Mining Production and Mining Operations Update for December 2025

Paul Yu, CEO and Director of Cango, commented, “Throughout 2025, Cango delivered strong and consistent operational growth. In December, due to favorable network difficulty adjustments, we maintained stable operating hashrate levels and achieved higher daily Bitcoin production, bringing our total Bitcoin holdings to 7,528.3 BTC. Additionally, in late December, a major shareholder decided to increase its investment in Cango with a US$10.5 million commitment, which expected to close in January 2026, representing a powerful vote of confidence in our strategic roadmap. This commitment will enable us to drive greater Bitcoin mining efficiency, and accelerate the parallel development of our energy and AI compute platform in 2026.”

About Cango Inc.

Cango Inc. (NYSE: CANG) is a Bitcoin mining company with a vision to establish an integrated, global infrastructure platform capable of powering the future digital economy. The Company’s mining operations span over 40 sites across North America, the Middle East, South America, and East Africa.

Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through AutoCango.com. 

For more information, please visit: www.cangoonline.com.

Investor Relations Contact
Juliet Ye, Head of Communications
Cango Inc.
Email: ir@cangoonline.com 

Christensen Advisory
Tel: +852 2117 0861
Email: cango@christensencomms.com

DUBAI, UAE, Jan. 5, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has launched a fully sponsored market literacy education initiative aimed at supporting financial literacy and responsible market understanding among Sri Lanka-based creators, in partnership with Mastering the Markets.

The online initiative is designed to upskill creators by providing a structured foundation in how financial markets operate, with an emphasis on accurate and responsible financial communication. Selected participants will receive access to a structured 10-week course covering market structure, technical analysis fundamentals, risk awareness, and disciplined decision-making.

Creators are selected through an application-based competition to participate in the fully sponsored market education initiative focused on foundational market knowledge and responsible financial communication.

The curriculum covers core principles of technical analysis and market behavior, including market structure, price action, trends, support and resistance, and risk management. The initiative is educational in nature and does not constitute financial, investment, or trading advice.

While certain examples within the course may reference digital asset markets, the analytical frameworks taught are broadly applicable across global financial markets. The program is intended to help creators develop a clearer understanding of market behavior and communicate financial concepts clearly and responsibly to their audiences.

“This structured 10-week program is designed to help creators strengthen their foundational market knowledge and communicate responsibly,” said David Bird, Founder & Chief Education Officer at Mastering the Markets. “By focusing on strong foundations and disciplined thinking, we help people build the knowledge and confidence needed to engage with markets responsibly and over the long term.”

“Education plays an important role in how people engage with financial markets,” said Nazar Tymoshchuk, Bybit’s Mini-Global Regional Manager. “This initiative supports structured learning by giving creators access to a clear, curriculum-based foundation that can be communicated in an accessible and responsible way.”

The initiative is open to Sri Lankan key opinion leaders who demonstrate a commitment to educating themselves and their communities. By combining foundational market education with exposure to both traditional financial markets and digital asset concepts, participants gain a broader educational framework for understanding global market behavior.

Upon completion of the course, participants will gain a clearer understanding of market dynamics, technical frameworks, and how structured market analysis methodologies are applied. The initiative aims to support the creation of more educational, accurate, and responsible financial content within Sri Lanka’s creator community.

Following earlier community-focused initiatives in Sri Lanka, the program reflects Bybit’s continued investment in education-focused engagement through partnerships with established market educators.

Sri Lankan creators interested in participating may submit their details through the official application form. Shortlisted participants will be contacted separately. More information about the initiative is available here.

#Bybit / #TheCryptoArk / #IMakeIt

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company,” 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱^®) in combination with MSD’s anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA^®[1]) was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS)≥1% and are EGFR-negative and ALK-negative. 

BTD is granted for treatment regimens that provide effective treatment or prevention for conditions with no currently available therapy, or that demonstrate significant clinical advantages over currently available treatments. For drugs included in the breakthrough therapy process, if relevant conditions are met, applications for conditional approval and priority review and approval can be submitted when applying for marketing authorization.

Previously, the company announced that results from the Phase III clinical trial of OptiTROP-Lung05, evaluating sac-TMT in combination with pembrolizumab as first-line treatment for PD-L1-positive NSCLC, demonstrated a statistically significant and clinically meaningful improvement in its primary endpoint of progression-free survival (PFS). A positive trend was also observed in overall survival (OS). OptiTROP-Lung05 is the first Phase III study of an immunotherapy and ADC combination to meet its primary endpoint in the first-line treatment of NSCLC. Granting of BTD for the first-line treatment of PD-L1-positive NSCLC indication offers pathways to expedite the review and potential approval process of sac-TMT for this indication.

To date, sac-TMT has received five BTDs for:

• locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022;
• locally advanced or metastatic EGFR-mutant NSCLC after progression on EGFR-TKI therapy in January 2023;
• locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023;
• first-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024;
• In combination with anti-PD-L1 monoclonal antibody tagitanlimab for the first-line treatment of locally advanced or metastatic non-squamous NSCLC without actionable genomic alterations in June 2025.

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, three indications for sac-TMT have been approved and marketed in China for: EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; Unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy. The first two indications listed above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinical benefits to a greater number of cancer patients.

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. In addition, the sNDA for sac-TMT for second-line and above treatment of HR+/HER2- BC was accepted by the Center for Drug Evaluation of the National Medical Products Administration, and was included in the priority review and approval process.

As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD has initiated 15 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

HO CHI MINH CITY, Vietnam, Jan. 5, 2026 /PRNewswire/ — JustMarkets, a worldwide broker with more than 12 years of experience in the online trading realm, is launching the Boost Contest, which represents a large-scale trading activity with the purpose of motivating traders, with the most proficient traders being awarded for their exceptional performance through a number of valuable prizes. This activity will last until the 31st of January, 2026.

A Competition Developed with the Goal of Providing More Opportunities for Traders Worldwide

Boost Contest competition participants will be traders with Standard, Pro, or Raw Spread accounts of the MetaTrader 4 or MetaTrader 5 platforms.

To participate, traders will only be required to have a minimum account balance of $100 with a minimum of 3 traded lots. These were the requirements set for participants. Of course, the purpose of such a competition is for every broker client to participate. At the same time, however, JustMarkets sought to encourage traders to conduct in-depth analysis, different strategies, risk, and discipline. It was with this objective that this form of competition was established.

Multiple-tier rewards system with real gold

What sets the Boost Contest apart is the Weekly Lucky Draws component, in which traders compete for real gold prizes, awarded in three levels, based on their cumulative trading volume achieved through the competition:

• Tier I (more than 100 lots): 15 grams of gold (3 winners)
• Tier II (50-99 lots): Gold worth 10 grams (5 winners)
• Tier III (10-49 lots): 5 grams of gold (7 winners)

This competition design thus provides traders with different levels of activity with the same opportunity of benefiting from valuable rewards.

Weekly Draws to Encourage Continued Participation

Apart from the top-level prizes, the competition also includes a series of weekly prizes. Traders participating in the competition will qualify for entry into the draw if they execute a minimum of three trades per week. Five lucky traders will be awarded $200 every week.

The introduction of the Boost Contest meets JustMarkets long-term obligations in:

• Engaging traders through effective rewards programs
• Fostering regular and organized trading practices
• Enhancing transparency and integrity within all promotion endeavors
• Offering a welcoming space where traders with different skill sets can participate

This reflects the purpose of JustMarkets, which is not only to offer traders good trading terms but also opportunities that add value to the entire trading experience.

A Global Platform Built on Trust and Innovation

As a globally recognized trading platform, JustMarkets continues to invest in initiatives that elevate client experience while adhering to high operational standards. The company maintains a robust technological infrastructure, offers multilingual support, and upholds strict security principles, all foundational elements behind long-term client trust.

The Boost Contest shows JustMarkets dedication to create a convenient and reliable trading environment where everyone can reach their full investment potential by clear rules, generous rewards, and a stable trading ecosystem.

About JustMarkets

JustMarkets is a global online trading broker that provides users with the ability to participate in international financial markets through innovative technology, advantageous trading conditions. JustMarkets provides traders with a variety of trading tools, such as forex currency pairs, worldwide indices, metals, cryptocurrencies, as well as stocks’ CFDs. JustMarkets provides its services in multiple languages, with a reliable trading environment, along with a customer-oriented policy.

LAS VEGAS, Jan. 5, 2026 /PRNewswire/ — Patriot Memory, a global leader in high-performance memory and storage solutions, will unveil its latest advancements at CES 2026, taking place January 6–9, 2026, in Las Vegas, Nevada. Building on decades of engineering expertise, Patriot’s CES 2026 showcase highlights the company’s continued focus on next-generation DDR5 memory and PCIe Gen5 storage technologies designed for enthusiasts, gamers, and professional users.

At CES 2026, Patriot Memory will present its newest innovations across both memory and storage under the Patriot and Viper Gaming brands, including:

Next-Generation DDR5 Memory

Viper Xtreme 5 Aurum Edition DDR5

The Viper Xtreme 5 Aurum Edition represents the pinnacle of Patriot’s DDR5 design philosophy, combining elite performance with refined aesthetics. Engineered for stability at high frequencies, the Aurum Edition delivers DDR5 speeds of up to 8000MT/s with capacities up to 64GB, paired with a premium, precision-crafted heat spreader design. Built for enthusiasts who demand both speed and visual distinction, the Aurum Edition embodies Patriot’s commitment to pushing DDR5 performance while maintaining elegance and reliability.

Viper Elite 5 Ultra DDR5

Designed specifically for Intel^® Core™ Ultra platforms, the Viper Elite 5 Ultra DDR5 series is optimized for next-generation Intel architectures. Offering DDR5 speeds up to 8000MT/s with capacities up to 96GB, Elite 5 Ultra delivers exceptional compatibility, efficiency, and stability for gamers and power users seeking a platform-focused memory solution tuned for modern workloads.

Viper Steel 5 DDR5

Rejoining Patriot’s CES 2026 lineup, Viper Steel 5 DDR5 continues to represent a balance of performance, capacity, and clean industrial design. Supporting speeds up to 8600MT/s with capacities up to 128GB, Viper Steel 5 is designed for high-performance systems that demand scalability, reliability, and broad platform compatibility.

New Model Prototype

Patriot will also preview a New Model Prototype DDR5 module, offering a glimpse into the company’s future memory roadmap. Demonstrated at speeds exceeding 10,000MT/s, with capacities to be determined, this engineering prototype highlights Patriot’s ongoing development around leading-edge platform compatibility, extreme performance targets, and forward-looking industrial design. The prototype underscores Patriot’s commitment to innovation across performance, stability, and aesthetics.

PCIe Gen5 SSD & Flash Storage Innovations

Flagship PCIe Gen5 SSD Family

Patriot’s CES 2026 storage showcase centers on its PCIe Gen5 SSD lineup, including the PV593, PV563, and PV563H. Designed to meet the demands of high-performance computing, content creation, and next-generation gaming, these drives leverage the latest PCIe Gen5 architecture to deliver exceptional throughput and responsiveness.

The flagship PV593 delivers sequential performance of up to 14,000MB/s read and 13,000MB/s write, with capacities up to 4TB, positioning it as Patriot’s highest-end Gen5 SSD for enthusiasts and professionals seeking uncompromising speed.

The PV563 and PV563H share the same core Gen5 architecture, offering sequential speeds of up to 14,000MB/s read and 11,000MB/s write, with capacities up to 4TB. As part of Patriot’s Gen5 SSD family evolution, graphene heat spreaders are now adopted as the standard thermal solution across the lineup, providing improved thermal efficiency and greater flexibility for space-constrained system configurations.

PV563H – Heatsink Edition

For users requiring enhanced thermal performance, the PV563H is available with a factory pre-installed aluminum fin heatsink. This plug-and-play solution enables immediate deployment without additional installation steps, delivering improved heat dissipation for sustained Gen5 performance under demanding workloads.

Commitment to Performance and Innovation

“CES 2026 is an important platform for showcasing how Patriot continues to evolve alongside next-generation computing,” said Les Henry, VP of Sales at Patriot Memory. “From the Aurum Edition DDR5 to our expanding Gen5 SSD family, our latest products reflect a relentless focus on performance, compatibility, and user-focused design.”

Experience Patriot at CES 2026

CES attendees are invited to experience Patriot Memory’s latest memory and storage technologies January 6–9, 2026, in Las Vegas, Nevada. Patriot’s showcase will highlight how the company continues to push the boundaries of speed, stability, and thermal design for the next era of computing.

About Patriot Memory™

Founded in 1985, Patriot Memory is a leading manufacturer of high-performance memory modules, SSDs, and flash storage solutions. Patriot is committed to technology innovation, quality engineering, and delivering competitive performance for gamers, creators, and professionals worldwide. Patriot products are sold globally through OEMs, retailers, e-tailers, and distributors across North America, South America, Asia, and Europe.

Introducing the Industry’s First Oral Care “Blind Box” Series: Miniature City Landmarks Designed to Inspire Greater Smiles; Interactive 3D Posting Boxes and and Themed Pop-up Stations to Debut Across Hong Kong

HONG KONG, Jan. 5, 2026 /PRNewswire/ — Authentic ‘Hong Kong Sentiments’ are often found within the most intimate details of daily life. As a global leader in oral care with a legacy spanning over 200 years, Colgate has grown alongside generations of Hong Kong families, witnessing the city’s evolution firsthand. To reinforce its commitment to professional care, Colgate is proud to unveil the ‘Hong Kong Sentiments’ Themed Toothbrush Collection in early 2026. This pioneering series reimagines iconic local landmarks through a lens of vibrancy and youthful creativity. By integrating these miniature city icons into premium toothbrush design, Colgate is also introducing the industry’s first ‘Blind Box’ concept, featuring limited-edition collectibles. This initiative seeks to transform the essential daily routine into an immersive journey of urban exploration, blending nostalgic sentiment with the element of surprise.

In conjunction with the product launch, Colgate will deploy a series of large-scale, toothbrush-themed ‘3D Posting box’ installations across Hong Kong, Kowloon, and the New Territories. These interactive landmarks, alongside a series of ‘Hong Kong Sentiments’ pop-up brand activations, are designed to engage the public in the heart of the city’s busiest districts. Visitors are invited to participate in these immersive experiences, where they can collect exclusive postcards and promotional vouchers. Through this campaign, Colgate encourages citizens to preserve their cherished memories of Hong Kong and embrace the New Year with a healthy, confident smile.

The collection is not merely a retrospective of the past, but an appreciation of the nuanced details that still resonate within our contemporary daily routines.

True ‘Hong Kong Sentiments’ extend beyond archival photographs, residing deeply within our collective sensory memories. Recognizing this unique urban pulse, Colgate has intentionally moved away from a somber, retrospective aesthetic for its new collection. Instead, the brand has chosen a vibrant, spirited design language to reinterpret the city’s essence. By artfully capturing the leisurely pace of the Star Ferry, the luminous skyline of Victoria Harbour, and the exuberant atmosphere of the Cheung Chau Bun Festival, Colgate has distilled these iconic silhouettes into minimalist designs, seamlessly integrating the spirit of Hong Kong into the daily oral care experience.

Through this distinctive design, Colgate aims to imbue the daily routine with a sense of the city’s singular charm and vitality. By celebrating these refined details of local life, the collection serves as a daily reminder for consumers to cherish their heritage while prioritizing professional oral health. Colgate‘s ultimate vision is to empower the people of Hong Kong to showcase their most healthy and confident smiles, embracing each day with a revitalized spirit and a profound appreciation for the city’s vibrant narrative.

Product Detail

A Highly Anticipated City-Wide Launch: Introducing the First-Ever ‘Miniature Landmark’ Blind Box Collection

To enhance the collectible value and engagement of the ‘Hong Kong Sentiments’ campaign, Colgate is pioneering the integration of the ‘Blind Box’ trend into the oral care category with the debut of the ‘Miniature Landmark’ Collectible Series. Each intricately crafted model artfully replicates Hong Kong’s iconic landmarks while playfully incorporating elements of Colgate‘s signature oral care products. Beginning January 2, 2026, customers can participate in this highly anticipated event. Upon purchasing any ‘Hong Kong Sentiments’ themed products or any Colgate/Plax products totaling HK$68 or more at major retail platforms, customers will receive one complimentary Blind Box* (distributed at random). Furthermore, ecom exclusive, limited-edition Blind Box^ will be available for online shoppers with any purchase of Colgate/Plax products totaling HK$128 or more at designated e-commerce stores—an initiative poised to ignite a city-wide collecting phenomenon.

Colgate envisions these miniature collectibles as versatile companions, whether displayed as calming desk ornaments or carried as functional keychains. By integrating these familiar silhouettes of the city into daily life, the brand seeks to provide a gentle reminder for individuals to embrace a confident, healthy smile. Ultimately, these collectibles serve as an inspiration to maintain a positive and optimistic perspective, empowering the community to navigate daily life with resilience and joy.

Limited-Time Engagement: Discover the Colgate “Hong Kong Sentiments” 3D Posting Box Installations

The excitement of the collection extends from the home to the streets of Hong Kong. To build on this momentum and encourage the community to share the spirit of the city alongside their healthy smiles, Colgate is proud to announce a series of interactive installations from January 9 to February 22, 2026. Strategic brand activations featuring the Colgate “Hong Kong Sentiments” 3D Posting boxes will debut at high-traffic urban hubs across Hong Kong, Kowloon, and the New Territories. These installations will showcase two exclusive commemorative designs: the “Tramway Heritage” edition and the “Victoria Harbour” edition. Members of the public are invited to capture creative photography with their miniature collectibles and share these moments of nostalgia and confident smiles across social media platforms.

Colgate Promotional Campaign: Experiencing Local Heritage Firsthand with a Series of Engaging City-wide Surprises

Furthermore, from January 10 to January 24, 2026, Colgate will host a series of promotional activations across four strategic urban hubs, including Tseung Kwan O, Ma On Shan, Aberdeen, and Tsuen Wan West. In a significant show of support for community wellness, in the upcoming Standard Chartered Hong Kong Marathon, Colgate is also setting up a dedicated cheer point in Tin Hau station to energize participants and spectators alike. These events will center on four interactive highlights: large-scale landmark installations and mascot for public engagement, the distribution of commemorative Hong Kong Sentiments postcards and product vouchers, and an exclusive opportunity to redeem a Colgate Total Plaque Release Toothpaste 18g upon presentation of a same-day purchase receipt. Through these vibrant initiatives and its marathon cheering event, Colgate seeks to integrate oral health awareness into the community’s active lifestyle, encouraging everyone to embrace challenges with a confident and healthy smile.

Colgate captivates social media with a visionary, larger-than-life tribute to Hong Kong, magnifying the city’s iconic landmarks alongside your healthy, confident smile.

To expand the reach of this campaign and share its energy with every corner of Hong Kong, Colgate is launching a series of breathtaking surrealist social media content. Designed to ignite online conversation through powerful visual impact, the campaign features larger-than-life “Hong Kong Sentiments” toothbrushes and oversized miniature landmarks. These visuals use a stunning scale to transform familiar urban silhouettes into extraordinary spectacles, perfectly embodying the brand’s unique philosophy: “Minimizing City Landmarks, Maximizing Healthy Smiles.” By bringing an unprecedented level of visual entertainment to the city, Colgate encourages the public to immerse themselves in this whimsical experience while showcasing their most confident and healthy smiles.

For more high-resolution images, please visit the link: http://bit.ly/4jhS5eB

Tags & Hashtags:

@colgate.hongkong #Colgate #ColgateHK #ColgateHKSentiments #ColgateHKSentimentsToothbrush #ColgateHKSentimentsBlindbox #HongKongSentiments #ColgateHealthySmiles #200YearsOfCare #MinimizingCityLandmarks #MaximizingHealthySmiles

About Colgate-Palmolive

Colgate-Palmolive is a global leader in household and personal care products, offering a wide range of products in oral care, personal care, home care, and pet nutrition. Colgate’s well-known brands are sold in over 200 countries and regions worldwide, including Colgate, Palmolive, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, Sanex, Ajax, Axion, Soupline, Suavitel, Hill’s Science Diet, Hill’s Prescription Diet, and Hill’s Ideal Balance.